Objective: There are currently no effective treatments to halt the muscle breakdown in Duchenne muscular dystrophy (DMD), although genetic-based clinical trials are being piloted. Most of these trials have as an endpoint the restoration of dystrophin in muscle fibers, hence requiring sufficiently well-preserved muscle of recruited patients. The choice of the muscles to be studied and the role of noninvasive methods to assess muscle preservation therefore require further evaluation.
Methods:We studied the degree of muscle involvement in the lower leg muscles of 34 patients with DMD Ͼ8 years, using muscle MRI. In a subgroup of 15 patients we correlated the muscle MRI findings with the histology of open extensor digitorum brevis (EDB) muscle biopsies. Muscle MRI involvement was assigned using a scale 0-4 (normal-severe).
Results:In all patients we documented a gradient of involvement of the lower leg muscles: the posterior compartment (gastrocnemius Ͼ soleus) was most severely affected; the anterior compartment (tibialis anterior/posterior, popliteus, extensor digitorum longus) least affected. Muscle MRI showed EDB involvement that correlated with the patient's age (p ϭ 0.055). We show a correlation between the MRI and EDB histopathologic changes, with MRI 3-4 grades associated with a more severe fibro-adipose tissue replacement. The EDB was sufficiently preserved for bulk and signal intensity in 18/22 wheelchair users aged 10-16.6 years.
Conclusion:This study provides a detailed correlation between muscle histology and MRI changes in DMD and demonstrates the value of this imaging technique as a reliable tool for the selection of muscles in patients recruited into clinical trials. Neurology ® 2011;76:346-353 GLOSSARY AO ϭ antisense oligonucleotide; DMD ϭ Duchenne muscular dystrophy; EDB ϭ extensor digitorum brevis; KAFO ϭ knee-ankle-foot orthosis; NSA ϭ number of signal averages; TE ϭ echo time; TR ϭ repetition time.The progressive loss of muscle fibers and their replacement by fat and connective tissue is part of the disease course of DMD.1 Despite several exhaustive natural history studies on the clinical course of DMD, the progression of pathology in individual muscle groups is poorly defined.
2Information on muscle pathology in DMD is limited to the muscles that are biopsied at the time of diagnosis (often quadriceps femoris), 2 the mean age at diagnosis being ϳ4.5 years. 3,4 There are now early clinical trials using novel genetic-based techniques in boys with DMD with the aim to restore dystrophin expression. These include the drug PTC124, 5 which allows